Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.002 AUD | -33.33% | -33.33% | -42.86% |
May. 16 | Avecho Biotechnology Doses First Patient in Phase III Anti-Insomnia Drug Trial | MT |
Mar. 25 | Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial | MT |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 7.887 | 6.31 | 46.37 | 27.54 | 27.57 | 11.09 |
Enterprise Value (EV) 1 | 5.719 | 3.196 | 44.66 | 24.37 | 26.35 | 5.763 |
P/E ratio | -1.97 x | 8 x | -17.1 x | -7.89 x | -11.5 x | -2.31 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 5.66 x | 1.49 x | 121 x | 34.7 x | 24.4 x | 23.4 x |
EV / Revenue | 4.1 x | 0.75 x | 116 x | 30.7 x | 23.3 x | 12.2 x |
EV / EBITDA | -1.31 x | 2.86 x | -15.6 x | -8.18 x | -12.5 x | -1.78 x |
EV / FCF | -3.05 x | 4.78 x | -59.8 x | -12.2 x | -30.5 x | -3.05 x |
FCF Yield | -32.8% | 20.9% | -1.67% | -8.17% | -3.28% | -32.8% |
Price to Book | 2.02 x | 1.33 x | 17.5 x | 6.07 x | 11.4 x | 1.74 x |
Nbr of stocks (in thousands) | 1,577,457 | 1,577,457 | 1,598,895 | 1,836,117 | 1,837,869 | 3,169,297 |
Reference price 2 | 0.005000 | 0.004000 | 0.0290 | 0.0150 | 0.0150 | 0.003500 |
Announcement Date | 3/26/19 | 3/1/20 | 3/25/21 | 2/27/22 | 3/15/23 | 2/29/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 1.394 | 4.238 | 0.3846 | 0.7936 | 1.129 | 0.4736 |
EBITDA 1 | -4.362 | 1.119 | -2.87 | -2.978 | -2.106 | -3.243 |
EBIT 1 | -5.088 | 0.515 | -3.407 | -3.406 | -2.336 | -3.421 |
Operating Margin | -364.91% | 12.15% | -885.8% | -429.2% | -206.86% | -722.46% |
Earnings before Tax (EBT) 1 | -3.991 | 0.85 | -2.635 | -3.416 | -2.342 | -3.437 |
Net income 1 | -3.991 | 0.85 | -2.635 | -3.416 | -2.342 | -3.437 |
Net margin | -286.24% | 20.06% | -685.04% | -430.46% | -207.43% | -725.7% |
EPS 2 | -0.002537 | 0.000500 | -0.001700 | -0.001900 | -0.001299 | -0.001515 |
Free Cash Flow 1 | -1.878 | 0.6684 | -0.7463 | -1.992 | -0.8644 | -1.891 |
FCF margin | -134.7% | 15.77% | -194.03% | -250.96% | -76.54% | -399.3% |
FCF Conversion (EBITDA) | - | 59.74% | - | - | - | - |
FCF Conversion (Net income) | - | 78.64% | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/26/19 | 3/1/20 | 3/25/21 | 2/27/22 | 3/15/23 | 2/29/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | 2.17 | 3.11 | 1.71 | 3.17 | 1.22 | 5.33 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow 1 | -1.88 | 0.67 | -0.75 | -1.99 | -0.86 | -1.89 |
ROE (net income / shareholders' equity) | -77.5% | 19.6% | -71.1% | -95% | -67.3% | -78.1% |
ROA (Net income/ Total Assets) | -48.8% | 6.36% | -49.1% | -49.5% | -34% | -40.1% |
Assets 1 | 8.184 | 13.36 | 5.364 | 6.901 | 6.892 | 8.57 |
Book Value Per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
Capex 1 | 0 | - | 0.01 | 0.2 | 0.05 | - |
Capex / Sales | 0.03% | - | 1.34% | 25.56% | 4.7% | - |
Announcement Date | 3/26/19 | 3/1/20 | 3/25/21 | 2/27/22 | 3/15/23 | 2/29/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-42.86% | 4.31M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- AVE Stock
- Financials Avecho Biotechnology Limited